The media database brings together all published information on platforms and products, as well as financial and corporate news.
Join our mailing list.
06/11/2016
“A Pilot Bioequivalence (BE) Study of Ultra-Rapid Concentrated BioChaperone® Lispro (BCLIS) U200 to BCLIS U100”, (Abstract 2242-PUB), presented by Dr. Grit Anderson, 76th Scientific Sessions of the American Diabetes Association, 10-14 June 2016, New Orleans, LO (USA)
06/10/2016
“Pharmacodynamic (PD) Profile of BioChaperone® Combo (BC Combo), a New Combination of Rapid-Acting and Long-Acting Insulin, in Subjects with Type 2 Diabetes Mellitus (T2DM)” (Poster 942), presented by Dr. Simon Bruce, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)
06/08/2016
Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon
06/06/2016
Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions
05/31/2016
Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects
04/27/2016
Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes
04/11/2016
Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100
03/21/2016
Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board
03/14/2016
Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes
02/16/2016
ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015
01/29/2016
Adocia and Lilly initiate Phase 1b study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects
12/15/2015
Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016
12/11/2015
Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100
11/25/2015
Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes
11/19/2015
Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the “Listed Company” category for the Grand Rhône-Alpes region
11/04/2015
Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes
10/06/2015
Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy
09/30/2015
Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes
08/27/2015
Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes
07/10/2015
Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo
06/26/2015
Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes
06/05/2015
“Ultra-Rapid BioChaperone® Insulin Lispro (BC LIS): Linear Dose-Response and Faster Absorption than Insulin Lispro (LIS)” (Poster 979), presented by Dr. Grit Anderson, 75th Scientific Sessions of the American Diabetes Association, 5-9 June 2015, Boston, MA (USA)
05/28/2015
Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015
05/26/2015
Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA)
05/04/2015
Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014
03/16/2015
Adocia will present its 2014 annual results and its perspectives of growth during a conference call
03/05/2015
Adocia opens a subsidiary in the USA and is pleased to appoint Simon Bruce, MD and Stephen Daly
02/05/2015
Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet
01/20/2015
Adocia initiates a clinical study on the post-meal effect of ultra-rapid BioChaperone Lispro insulin formulation
12/19/2014
Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology
09/30/2014
ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry
Join our mailing list. Subscribe